Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

Cancer Science

Volumn 102, Issue 2, 2011, Pages 425-431

  Okusaka, Takuji ^a   Furuse, Junji ^b,c   Funakoshi, Akihiro ^d   Ioka, Tatsuya ^e   Yamao, Kenji ^f   Ohkawa, Shinichi ^g   Boku, Narikazu ^h   Komatsu, Yoshito ⁱ   Nakamori, Shoji ^j   Iguchi, Haruo ^k   Ito, Tetsuhide ^l   Nakagawa, Kazuhiko ^m   Nakachi, Kohei ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

^m KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEMCITABINE;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ERYTHROCYTE COUNT; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOCRIT; HUMAN; INOPERABLE CANCER; INTERSTITIAL LUNG DISEASE; JAPANESE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PUSTULAR RASH; RASH; SIDE EFFECT; SKIN EXFOLIATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; UNRESECTABLE PANCREAS CANCER; UNRESECTABLE PANCREATIC CANCER; WEIGHT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, ADENOSQUAMOUS; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES;

EID: 79952095727     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01810.x     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Japanese Ministry of Health, Labour and Welfare. Statistical investigation result 2005. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: .
3. Japanese Ministry of Health, Labour and Welfare. Table database system. (In Japanese.) [Cited 16 Feb 2010.] Available from URL: .
4. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
5. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-5.
6. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-10.
7. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83.
8. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-16.
9. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-45.
10. Abou-Alfa GK, Letourneau R, Harker G et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-7.
11. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-52.
12. Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95: 587-92.
13. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-7.
14. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-8.
15. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
16. Moore M, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-302.
17. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [Pca]: SWOG S0205 study. J Clin Oncol 2007; 25 (Suppl 18): 199s (Abstract LBA4509).
18. Kindler HL, Niedzwiecki D, Hollis E et al. A double-blind, placebo-controlled, randomizes phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 2007; 25 (Suppl 18): 199s (Abstract 4508).
19. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7.
20. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-21.
21. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-46.
22. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30: 3-14.
23. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-14.
24. Jost M, Gasparro FP, Jensen PJ et al. Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation - differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression. J Invest Dermatol 2001; 116: 860-6.
25. Quon H, Liu F, Cummings B. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-59.
26. Ueda S, Ogata S, Tsuda H et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29: e1-8.
27. Durkin A, Bloomston PM, Rosemurgy AS et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 2003; 186: 431-6.
28. Moore M, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
29. Kubota K, Nishiwaki Y, Tamura T et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008; 3: 1439-45.
30. Dragovich T, Huberman M, Von Hoff DD et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2007; 60: 295-303.
31. Honeywell R, Laan AC, van Groeningen CJ et al. The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 142-52.
32. Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19: 209-16.
33. Nakamura K, Yamaguchi T, Ishihara T et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-9.
34. Tanaka T, Ikeda M, Okusaka T et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 755-61.
35. Tamiya A, Endo M, Shukuya T et al. Features of gemcitabine-related severe pulmonary toxicity patients with pancreatic or biliary tract cancer. Pancreas 2009; 38: 838-40.
36. Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 73-7.
37. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 2549-56.
38. Kudoh S, Kato H, Nishiwaki N et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177: 1348-57.
39. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006; 23: 161-70.
40. Yoneda KY, Shelton DK, Beckett LA et al. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2: 537-43.
41. Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21.
42. Van Cutsem E, Vervenne WL, Bennouna J et al. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. Proc ASCO Gastrointestinal Cancers Symposium, 2009 (Abstr 117). [Cited 16 Feb 2010.] Available from URL: .
43. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
44. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 28: 4268-75.
45. Immervoll H, Hoem D, Kugarajh K et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006; 448: 788-96.
46. Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561-9.
47. Tzeng CW, Frolov A, Frolova N et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007; 141: 464-9.